ZETA : Prospective Observational Study

Sponsor
Recherche clinique
Study ID
NCT03730558
Status
Completed

Conditions

  • Metastatic Colon Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Primary objective \- Evaluate the efficacy in terms of progression-free survival (PFS) of aflibercept in combination with FOLFIRI in patients treated routinely for metastatic colorectal cancer (mCRC) after failure of treatment with oxaliplatin + EGFR. Secondary objective * Evaluate the efficacy of aflibercept in combination with FOLFIRI on the 2-year overall survival rate and the objective response rate. * Evaluate the tolerance profile of aflibercept in combination with FOLFIRI. * Observational study, national, multicenter, cohort, prospective without intervention on the therapeutic strategy.•

Key Dates

Start date
Nov 8, 2017
Status verified
Jun 2023
Primary completion
Nov 8, 2021
Completion
Nov 8, 2021

Study Design

Enrollment
120 participants (actual)

Primary Outcome Measure

Evaluate the efficacy of aflibercept in terms of progression-free survival (PFS) in association with FOLFIRI in patients treated in common practice for metastatic colorectal cancer (CCRM) after failure of oxaliplatin + anti-EGFR-based treatment [ Time Frame: 2 years ]

Related Studies